Amussen Hunsaker Associates LLC Galectin Therapeutics Inc Transaction History

Amussen Hunsaker Associates LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$2.53 - $3.64 $43,237 - $62,207	-17,090 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.79 - $4.32 $47,681 - $73,828	17,090 New	17,090 $49,000
Q3 2019 Nov 15, 2019	SELL	$3.0 - $4.05 $51,270 - $69,214	-17,090 Closed	0 $0
Q2 2019 Aug 20, 2019	BUY	$3.61 - $5.0 $61,694 - $85,450	17,090 New	17,090 $71,000
Q1 2019 May 16, 2019	SELL	$3.86 - $6.02 $65,967 - $102,881	-17,090 Closed	0 $0
Q3 2018 Nov 16, 2018	BUY	$3.68 - $6.93 $60,352 - $113,652	16,400 Added 2376.81%	17,090 $79,000
Q2 2018 Aug 16, 2018	BUY	$3.16 - $9.16 $2,180 - $6,320	690 New	690 $4,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $61.8M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Amussen Hunsaker Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Amussen Hunsaker Associates LLC with notifications on news.